Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005
- 28 June 2007
- journal article
- pharmacoepidemiology and-prescription
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 63 (9) , 843-849
- https://doi.org/10.1007/s00228-007-0320-6
Abstract
The purpose of this study was to examine recent trends in the prescribing of hormone therapy for menopause, tibolone, and bisphosphonate preparations for the prevention or treatment of osteoporosis, in the UK in relation to publication of research evidence on the health effects of hormone therapy and subsequent changes in prescribing advice.Keywords
This publication has 24 references indexed in Scilit:
- Decline in use of hormone therapy among postmenopausal women in the United KingdomMenopause, 2007
- LIFT study is discontinuedBMJ, 2006
- Tibolone and Endometrial CancerDrug Safety, 2005
- Effects of Conjugated Equine Estrogen in Postmenopausal Women With HysterectomyJAMA, 2004
- Breast cancer and hormone-replacement therapy in the Million Women StudyThe Lancet, 2003
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancerThe Lancet, 1997
- Validation of information recorded on general practitioner based computerised data resource in the United Kingdom.BMJ, 1991
- Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidencePreventive Medicine, 1991
- A Prospective Study of Postmenopausal Estrogen Therapy and Coronary Heart DiseaseNew England Journal of Medicine, 1985